Market Overview:
The global squamous non-small cell lung cancer therapeutics market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as the increasing incidence of squamous non-small cell lung cancer, rising demand for novel therapies, and growing focus on personalized medicine. However, the high cost of treatment and lack of reimbursement are some factors that could restrain the growth of this market. The global squamous non-small cell lung cancer therapeutics market is segmented on the basis of type, application, and region. On the basis of type, it is divided into BMS-906024, buparlisib hydrochloride FP-1039 ipilimumab JNJ 42756493 lenvatinib others). On the basis of application it is classified into research center hospital clinic). Region wise, it covers North America Latin America Europe Asia Pacific Middle East & Africa).
Product Definition:
Squamous non-small cell lung cancer is the most common type of lung cancer. It starts in the cells that line the air passages in the lungs. The tumor may grow slowly and not cause any symptoms for a long time. When it does cause symptoms, they may include coughing up blood, chest pain, shortness of breath, or wheezing.
There is no cure for squamous non-small cell lung cancer, but treatment can help control the disease and improve quality of life. Treatment options include surgery, radiation therapy, chemotherapy, targeted therapy drugs (such as bevacizumab), and immunotherapy drugs (such as nivolumab).
BMS-906024:
BMS-906024 is a member of the Bcl-2 family. It protects cells from death by regulating the pro-apoptotic process. The drug has shown potent anti-cancer activity in vitro and in vivo, with an EC50 value of 0.31 uM and 3 respectively.
Buparlisib Hydrochloride:
Buparlisib hydrochloride is a drug developed by Eli Lilly and Company. It is an investigational anti-cancer drug with the molecular formula C23H30N4O2S and a molecular weight of 434.3. The chemical structure of the compound was first created by Dr.
Application Insights:
The research center application segment dominated the global market in 2017. This can be attributed to the rising number of clinical trials for various cancer types and increasing government funding for cancer research. For instance, as per the statistics published by NCBI, there are currently over 200 active clinical trials being conducted for NSCLC patients.
The hospital application segment is expected to witness lucrative growth during the forecast period due to an increase in prevalence of different cancers worldwide and growing awareness about early diagnosis among patients. According to WHO, around 1 person dies from lung cancer every 3 seconds globally which accounts for around 15% of all lung-related deaths annually. Thus, rising incidence rates coupled with high mortality rates are anticipated to boost demand from hospital applications during the forecast period.
Moreover, increasing R&D investments by major companies such as Pfizer Inc., Merck KGaA., Novartis AG., Eli Lilly & Company LLC., Astrazeneca PLC., Bayer HealthCare LLC.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable government initiatives, and high adoption rate for novel therapeutics are some of the factors responsible for its large share. For instance, in November 2016, the U.S FDA approved Bupropion Hydrochloride Extended-Release Tablets 150 mg & 300 mg Composition Of Same Active Ingredient As Well as New Drug Application (NDA) for once-daily treatment of adults with SK2 & SK3 resistant depression.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income and improving healthcare infrastructure coupled with increasing awareness about available treatments among patients suffering from lung cancer type squamous cell carcinoma (SCC). In addition, growing penetration of generic drugs due to patent expirations or regulatory approvals by regulatory authorities would further boost revenue growth during the forecast period.
Growth Factors:
- Increasing incidence of squamous non-small cell lung cancer (NSCLC)
- Rising demand for better and more effective therapies for squamous NSCLC
- Growing awareness about squamous NSCLC and its treatment options
- increasing investment in research and development of new therapies for squamous NSCLC
- Availability of novel targeted therapies and immunotherapies
Scope Of The Report
Report Attributes
Report Details
Report Title
Squamous Non-Small Cell Lung Cancer Therapeutics Market Research Report
By Type
BMS-906024, Buparlisib Hydrochloride, FP-1039, Ipilimumab, JNJ-42756493, Lenvatinib, Others
By Application
Research Center, Hospital, Clinic
By Companies
Ascenta Therapeutics, Inc., AstraZeneca Plc, AVEO Pharmaceuticals, Inc., Bayer AG, BIND Therapeutics, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Five Prime Therapeutics, Inc., Genentech, Inc., Incyte Corporation, Johnson & Johnson, MacroGenics, Inc., Novartis AG, Oncogenex Pharmaceuticals, Inc., PsiOxus Therapeutics Limited
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
245
Number of Tables & Figures
172
Customization Available
Yes, the report can be customized as per your need.
Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Report Segments:
The global Squamous Non-Small Cell Lung Cancer Therapeutics market is segmented on the basis of:
Types
BMS-906024, Buparlisib Hydrochloride, FP-1039, Ipilimumab, JNJ-42756493, Lenvatinib, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Research Center, Hospital, Clinic
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Ascenta Therapeutics, Inc.
- AstraZeneca Plc
- AVEO Pharmaceuticals, Inc.
- Bayer AG
- BIND Therapeutics, Inc.
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Five Prime Therapeutics, Inc.
- Genentech, Inc.
- Incyte Corporation
- Johnson & Johnson
- MacroGenics, Inc.
- Novartis AG
- Oncogenex Pharmaceuticals, Inc.
- PsiOxus Therapeutics Limited
Highlights of The Squamous Non-Small Cell Lung Cancer Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- BMS-906024
- Buparlisib Hydrochloride
- FP-1039
- Ipilimumab
- JNJ-42756493
- Lenvatinib
- Others
- By Application:
- Research Center
- Hospital
- Clinic
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Squamous Non-Small Cell Lung Cancer Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Squamous non-small cell lung cancer (NSCLC) is a type of lung cancer that is characterized by the presence of squamous cells in the tumor. Squamous cells are a type of cell that make up the surface layer of the lungs. NSCLC is one of the most common types of lung cancer, and it accounts for about 30% to 40% of all cases. There are many different treatments available for NSCLC, but there is no cure currently available. Treatment options include surgery, chemotherapy, and radiation therapy.
Some of the major companies in the squamous non-small cell lung cancer therapeutics market are Ascenta Therapeutics, Inc., AstraZeneca Plc, AVEO Pharmaceuticals, Inc., Bayer AG, BIND Therapeutics, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Five Prime Therapeutics, Inc., Genentech, Inc., Incyte Corporation, Johnson & Johnson, MacroGenics, Inc., Novartis AG, Oncogenex Pharmaceuticals, Inc., PsiOxus Therapeutics Limited.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Squamous Non-Small Cell Lung Cancer Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Squamous Non-Small Cell Lung Cancer Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Squamous Non-Small Cell Lung Cancer Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Squamous Non-Small Cell Lung Cancer Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Squamous Non-Small Cell Lung Cancer Therapeutics Market Size and Y-o-Y Growth
4.5.2 Squamous Non-Small Cell Lung Cancer Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Type
5.2.1 BMS-906024
5.2.2 Buparlisib Hydrochloride
5.2.3 FP-1039
5.2.4 Ipilimumab
5.2.5 JNJ-42756493
5.2.6 Lenvatinib
5.2.7 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Applications
6.2.1 Research Center
6.2.2 Hospital
6.2.3 Clinic
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Squamous Non-Small Cell Lung Cancer Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Type
9.6.1 BMS-906024
9.6.2 Buparlisib Hydrochloride
9.6.3 FP-1039
9.6.4 Ipilimumab
9.6.5 JNJ-42756493
9.6.6 Lenvatinib
9.6.7 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Applications
9.10.1 Research Center
9.10.2 Hospital
9.10.3 Clinic
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Type
10.6.1 BMS-906024
10.6.2 Buparlisib Hydrochloride
10.6.3 FP-1039
10.6.4 Ipilimumab
10.6.5 JNJ-42756493
10.6.6 Lenvatinib
10.6.7 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Applications
10.10.1 Research Center
10.10.2 Hospital
10.10.3 Clinic
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Type
11.6.1 BMS-906024
11.6.2 Buparlisib Hydrochloride
11.6.3 FP-1039
11.6.4 Ipilimumab
11.6.5 JNJ-42756493
11.6.6 Lenvatinib
11.6.7 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Applications
11.10.1 Research Center
11.10.2 Hospital
11.10.3 Clinic
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Type
12.6.1 BMS-906024
12.6.2 Buparlisib Hydrochloride
12.6.3 FP-1039
12.6.4 Ipilimumab
12.6.5 JNJ-42756493
12.6.6 Lenvatinib
12.6.7 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Applications
12.10.1 Research Center
12.10.2 Hospital
12.10.3 Clinic
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Squamous Non-Small Cell Lung Cancer Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Type
13.6.1 BMS-906024
13.6.2 Buparlisib Hydrochloride
13.6.3 FP-1039
13.6.4 Ipilimumab
13.6.5 JNJ-42756493
13.6.6 Lenvatinib
13.6.7 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Applications
13.10.1 Research Center
13.10.2 Hospital
13.10.3 Clinic
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Squamous Non-Small Cell Lung Cancer Therapeutics Market: Competitive Dashboard
14.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Ascenta Therapeutics, Inc.
14.3.2 AstraZeneca Plc
14.3.3 AVEO Pharmaceuticals, Inc.
14.3.4 Bayer AG
14.3.5 BIND Therapeutics, Inc.
14.3.6 Boehringer Ingelheim GmbH
14.3.7 Bristol-Myers Squibb Company
14.3.8 Eli Lilly and Company
14.3.9 F. Hoffmann-La Roche Ltd.
14.3.10 Five Prime Therapeutics, Inc.
14.3.11 Genentech, Inc.
14.3.12 Incyte Corporation
14.3.13 Johnson & Johnson
14.3.14 MacroGenics, Inc.
14.3.15 Novartis AG
14.3.16 Oncogenex Pharmaceuticals, Inc.
14.3.17 PsiOxus Therapeutics Limited
